Hepatic manifestations of gastrointestinal diseases

Smyth, C; Kelleher, Dermot; Keeling, P. W. N.

doi:10.1016/s1089-3261(02)00055-7

Cited by 24 publications

(3 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of other IBD‐associated liver diseases, PBC also has been reported, but occurs much less frequently than PSC (79). NAFLD is generally related to nutritional status, medication use, or comorbid factors such as diabetes (79). Other less frequently encountered associations are listed in Table 2.…”

Section: Hepatic Manifestations Of Ibdmentioning

confidence: 99%

The Liver in Pediatric Gastrointestinal Disease

Rabinowitz

et al. 2014

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Hepatic involvement is often encountered in gastrointestinal (GI) diseases, in part because of the close anatomic and physiologic relations between the liver and GI tract. Drainage of the mesenteric blood supply to the portal vein permits absorbed and/or translocated nutrients, toxins, bacterial elements, cytokines, and immunocytes to gain hepatic access. Liver problems in digestive disorders may range from nonspecific hepatocellular enzyme elevations to significant pathologic processes that may progress to end-stage liver disease. Hepatobiliary manifestations of primary GI diseases in childhood and adolescence are not uncommon and include several well-described associations, such as sclerosing cholangitis with inflammatory bowel disease. Liver damage may also result from the effects of drugs used to treat GI diseases, for example, the hepatotoxicity of immunomodulatory therapies. This review highlights the important features of the hepatic and biliary abnormalities associated with 3 common pediatric GI conditions: inflammatory bowel disease, celiac disease, and cystic fibrosis.

show abstract

Section: Hepatic Manifestations Of Ibdmentioning

confidence: 99%

The Liver in Pediatric Gastrointestinal Disease

Rabinowitz

et al. 2014

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…Although it is expected that PSC patients with HLA DR3, DQ2 haplotype would be at risk of CD, such patients have previously been noted to exhibit a more rapid progression of liver disease. Therefore one could imagine whether or not patients with CD who develop PSC suffer from more aggressive liver disease than those without CD[ 45 ]. Although this has not been specifically studied, in a previous study, patients with high AGA titers demonstrated advanced portal fibrosis[ 46 ].…”

Section: Pscmentioning

confidence: 99%

To screen or not to screen? Celiac antibodies in liver diseases

Narciso-Schiavon

Schiavon

2017

WJG

View full text Add to dashboard Cite

Celiac disease (CD) is a systemic immune-mediated disorder triggered by dietary gluten in genetically predisposed individuals. The typical symptoms are anemia, diarrhea, fatigue, weight loss, and abdominal pain. CD has been reported in patients with primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, aminotransferase elevations, nonalcoholic fatty liver disease, hepatitis B, hepatitis C, portal hypertension and liver cirrhosis. We evaluate recommendations for active screening for CD in patients with liver diseases, and the effect of a gluten-free diet in these different settings. Active screening for CD is recommended in patients with liver diseases, particularly in those with autoimmune disorders, steatosis in the absence of metabolic syndrome, noncirrhotic intrahepatic portal hypertension, cryptogenic cirrhosis, and in the context of liver transplantation. In hepatitis C, diagnosis of CD can be important as a relative contraindication to interferon use. Gluten-free diet ameliorates the symptoms associated with CD; however, the associated liver disease may improve, remain the same, or progress.

show abstract

“…Regarding prognosis, it is conceivable that each disease could negatively influence the outcome of the others. In fact, 5% of IBD patients develop a severe liver disease [20]. On the other hand, NAFLD, especially in its progressive form (NASH), might make clinical management of IBD particularly difficult [21].…”

Section: Introductionmentioning

confidence: 99%

The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease

et al. 2021

View full text Add to dashboard Cite

Steatohepatitis and hepatobiliary manifestations constitute some of the most common extra-intestinal manifestations of Inflammatory Bowel Disease (IBD). On the other hand, non-alcoholic fatty liver disease (NAFLD) affects around 25% of the world’s population and is attracting ever more attention in liver transplant programs. To outline the specific pathways linking these two conditions is a pressing task for 21st-century researchers. We are accustomed to expecting the occurrence of fatty liver disease in obese people, but current evidence suggests that there are several different pathways also occurring in underweight patients. Genetic factors, inflammatory signals and microbiota are key players that could help in understanding the entire pathogenesis of NAFLD, with the aim of defining the multiple expressions of malnutrition. In the current review, we summarize the most recent literature regarding the epidemiology, pathogenesis and future directions for the management of NAFLD in patients affected by IBD.

show abstract

Hepatic manifestations of gastrointestinal diseases

Cited by 24 publications

References 68 publications

The Liver in Pediatric Gastrointestinal Disease

The Liver in Pediatric Gastrointestinal Disease

To screen or not to screen? Celiac antibodies in liver diseases

The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About